Quest Diagnostics Incorporated (DGX)
DGX historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in DGX.
DGX annual returns by year
Congress trading in DGX
8 members of Congress have disclosed trading DGX — 4 purchases and 9 sales worth an estimated $128,500. Most recent disclosure: Oct 30, 2025.
See who in Congress traded DGX →Insider activity in DGX
DGX's own executives and directors have made 0 open-market purchases ($0) and 3 sales ($3.9M) in the last 90 days, per SEC Form 4 filings. Most recent: Jul 28, 2026.
| Jul 28, 2026 | Delaney Mark E | SVP & Chief Commercial Officer | Sell | $376,288 |
| Jun 4, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | Sell | $1.6M |
| Jun 1, 2026 | Davis J. E. | CEO and President | Sell | $1.9M |
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
DGX Key Statistics
DGX in plain English
- P/E ratio (26.0) — how many dollars you pay for each $1 of DGX's yearly profit. That's a fairly normal range.
- ROE (14.60%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (9.19%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (1.41%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
DGX stock: frequently asked questions
What is Quest Diagnostics Incorporated's stock price today?
Quest Diagnostics Incorporated (DGX) last traded at $244.51 on the NYSE. Over the past 52 weeks the stock has traded between $171.18 and $246.00.
How much would $1,000 invested in DGX 10 years ago be worth today?
A $1,000 investment in Quest Diagnostics Incorporated made 10 years ago would be worth about $3,598 today (dividends reinvested) — a total return of 260%, or 13.7% per year.
Does DGX pay a dividend?
Yes. Quest Diagnostics Incorporated currently pays a dividend yielding about 1.41% per year at today's share price.
What is DGX's P/E ratio?
DGX trades at a trailing price-to-earnings ratio of 26.0, and 20.3 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade DGX stock?
Yes — 8 members of Congress have disclosed trades in DGX under the STOCK Act, totaling 4 purchases and 9 sales worth an estimated $128,500.
What is Quest Diagnostics Incorporated's ticker symbol?
Quest Diagnostics Incorporated trades under the ticker symbol DGX on the NYSE.
Compare DGX with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.